z-logo
open-access-imgOpen Access
Development of a Novel Surrogate Virus for Human T-Cell Leukemia Virus Type 1: Inhibition of Infection by Osteoprotegerin
Author(s) -
Kazu Okuma,
Kevin P. Dalton,
Linda Buonocore,
Elizabeth Ramsburg,
John K. Rose
Publication year - 2003
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.77.15.8562-8569.2003
Subject(s) - vesicular stomatitis virus , biology , virology , osteoprotegerin , glycoprotein , virus , transmembrane protein , viral envelope , recombinant dna , microbiology and biotechnology , gene , biochemistry , receptor , activator (genetics)
To develop a high-titer surrogate virus for human T-cell leukemia virus type 1 (HTLV-1), we generated recombinant vesicular stomatitis viruses (VSVs) in which the gene encoding the single transmembrane glycoprotein (G) was deleted. Genes encoding HTLV-1 envelope glycoproteins (HTEnv) or HTEnvG hybrid proteins were then inserted into either of two different sites in the VSV genome. The viruses also encoded a green fluorescent protein. With this surrogate virus, we found that a soluble protein, osteoprotegerin (OPG), or an OPG/Fc chimeric protein inhibited the infection of various cell lines. Our experiments indicate that this inhibition resulted from binding of heparan sulfate by OPG.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here